Sherene Loi, MD
@LoiSher
Professor, Medical Oncologist, #LoiLab @PeterMacCC @UniMelb @NBCFAus Endowed Chair, #IBSCG cochair @etop_ibcsg, @TILsWorkgroup cofounder; own views
Our latest review is out now on targeting #BreastCancer #Immunity #tme #trm #CancerResearch many thanks to @NatureRevCancer @PeterMacCC @PeterMacRes @TILsWorkGroup
Towards targeting the breast cancer immune microenvironment dlvr.it/T9C7GF
🏁latest review from #loilab & our Spanish colleagues #vhio #bcsm @OncoAlert @TILsWorkGroup Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer thebreastonline.com/article/S0960-…
Excited to share our latest publication from the EN-SEMBLE study in ESMO Open! @ESMO_Open Post-T-DXd therapy is a major unmet need in HER2+ mBC. This large, real-world study provides insights into treatment patterns, outcomes, and the risk of ILD. 👉 doi.org/10.1016/j.esmo…
#bcsm 💊💉we really need more efficacious drugs!
A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group’s (DBCG) NAME-trial buff.ly/sFujDK2 The NAME trial, a randomized phase II study, compared metronomic (daily low-dose) oral…
(Breast) Cancer care shouldn’t be a luxury. We lose lives not just to cancer, but to lack of access, high costs, and trials that exclude too many. Innovation must reach every patient, everywhere! @Nature @curijoey @LoiSher @myESMO @ASCO @BreastCancerNow @tmprowell @uicc…
🏃♀️🏋️🏋️♂️🎾👟Further evidence on the benefit of physical activity #exercise #strength training for chronic medical conditions from a RCT rdcu.be/evps3 @NatureMedicine
JCOG1017 trial found that primary tumor resection (PTR) did not prolong overall survival in de novo Stage IV breast cancer. However, it improved local control and might benefit subsets like premenopausal patients or those with single-organ metastasis. @JGbreast @TADSHIEN…
“Who decides who decides?” An editorial based on @rebeccampbell50 & @LauraBukavinaMD’s work in which we explore how altmetrics & digital clout are shaped by systemic bias. Honored to cowrite this with @DrSGraff 🔗 ascopubs.org/doi/10.1200/OP… #MedTwitter #WomenInMedicine
😂🤩 @andy_murray
Andy Murray giving life advice to random fans is as good as you imagine it would be 🤣 Agony Andy at your service 🫡 #HSBCChampionships @andy_murray
Given recent amazing results from Rand P3 study by Zheng et al, #ASCO25 on Chrono-IO (PD-1 before 3 pm vs after; HR 0.42), #circadian clocks are topical- but is it fit-patient bias? Broad aspirational review below from @NatureCancer @OncoAlert ⭐️also many new drugs have PK/PD…
⭐️This study reinforces that treating upfront with the strongest targeted 🎯 combination will alter the natural history of disease & ⬆️ OS. We've seen it for #HER2 Better pharmacology has & will improve tolerabilty, AE profile & 🔽discontinuations @NEJM #bcsm #breastcancer
In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. Full INAVO120 trial results: nej.md/3Zje7Vt #ASCO25 | @ASCO
🚩Final results of IMpassion031👏neoadj Atezo in early #TNBC Final EFS HR~ Gepardouze. ctDNA neg by Signatera not sensitive enough to say patients are cured but small % who were pos did poorly. Hopefully next gen ctDNA assays will be better. #bcsm @NatureMedicine…
Keynote by Sherene Loi at #ESMOBreast25 🔹 Pregnancy & breastfeeding may reprogram the breast immune environment, enhancing early cancer detection. 🔹 HR+ breast cancer may respond to immunotherapy if biologically selected (CheckMate 7FL). @myESMO @OncoAlert @oncodaily
informative censoring vs ITT analyses.-a problem for all studies of exercise in cancer patients I suspect
x.com/i/article/1930…
Good morning all. After yesterday's excitement about the CHALLENGE exercise trial, here is my critical appraisal on @Sensible__Med #ASCO25
👏👏amazing 40m med PFS with TDXD+P v 20m THP. If 2L TDXD (DB03) is 28m PFS v 6m TDM1, does the maths favour 1L THP➡️2L TDXD? +add Palbo? Esp as 1L TDXD may make 2L TDM1 less effective (down reg HER2). Potentially 1L DB09 may ⬆️ CNS control. Def need OS - are some patients…
Impressive 40.7 months mPFS with TDXd and pertuzumab! This may represents a new SOC as 1st line therapy for patients with HER2 positive MBC @stolaney1 @AstraZeneca @DaiichiSankyoUS @OncoAlert
Oral abstract session at #ASCO25 with 15-y follow-up data from @etop_ibcsg SOFT & TEXT trials…proper risk stratification is needed to optimize adjuvant endocrine therapy in premenopausal women with #BreastCancer @OncoAlert
bravo #ASCO25 👏👏👏👏
Presented at #ASCO25: In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results:…